Article ID Journal Published Year Pages File Type
3392461 Transplant Immunology 2008 9 Pages PDF
Abstract

We have developed a model of aortic allograft vasculopathy (AV) that uses mouse strains that are fully disparate at Class I, Class II and minor histocompatibility antigens. Acute rejection is ablated with therapeutic doses of the calcineurin inhibitor Cyclosporine A (CyA). In this way we successfully mimic human disease. Using this model we have demonstrated, with cell transfer models using highly purified T cell populations, that calcineurin inhibitors ablate CD4+ T cell effector mechanisms. As such, in the presence of calcineurin inhibition, graft vasculopathy is dependent on CD8+ T cell effector mechanisms.In this study we examine the etiology of graft vasculopathy by these CD8+ T cells in the presence of calcineurin inhibition. We transferred CD8+ T cells from CyA treated IFN-γ deficient mice into immunodeficient mouse recipients of aortic allografts to demonstrate that IFN-γ production by CD8+ T cells is essential for the development of AV in the presence of calcineurin inhibition. Using two models of CTL ablation we also demonstrated that CTL activity by CD8+ T cells is essential for the development of AV in the presence of calcineurin inhibition. This is in contrast to models without calcineurin inhibitor immunosuppression where either pathway is capable, by itself, of inducing AV.These data indicate that although calcineurin inhibition ablates CD4+ T cell effects and weakens CD8+ T cell pathways, the antigenic challenge of the graft is enough to induce sufficient responsiveness from CD8+ T cells to induce robust AV.

Related Topics
Life Sciences Immunology and Microbiology Immunology
Authors
, , , ,